Passage Bio Inc (PASG)
2.55
-0.21 (-7.61%)
USD |
NASDAQ |
Jun 24, 16:00
2.20
-0.35 (-13.73%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 138.48M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -82.35% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.4923 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Globe Newswire
06/09 07:30
MT Newswires
06/08 07:58
Globe Newswire
06/08 07:30
MT Newswires
06/01 07:50
Yahoo
05/18 07:00
MT Newswires
05/17 08:42
MT Newswires
05/17 08:41
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/05/2022* | -- | Results | Q2 2022 | -- | -0.78 | -- | |
| 08/05/2022* | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/16/2022 | -- | Results | Q1 2022 | -0.79 | -0.92 | 14.04% | |
| 05/16/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 03/03/2022 | -- | Results | Q4 2021 | -0.95 | -0.86 | -10.42% | |
| 03/03/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/04/2021 | -- | Results | Q3 2021 | -0.87 | -0.87 | -0.01% | |
| 11/04/2021 | 08:30 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. |
| URL | https://www.passagebio.com |
| Investor Relations URL | https://investors.passagebio.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 05, 2022 (est.) |
| Last Earnings Release | May. 16, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of June 24, 2022.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 181.61M |
| Net Income (TTM) | -189.32M |
| Total Assets (Quarterly) | 333.22M |
| Total Liabilities (Quarterly) | 51.91M |
| Shareholders Equity (Quarterly) | 281.31M |
| Cash from Operations (TTM) | -140.87M |
| Cash from Investing (TTM) | -8.106M |
| Cash from Financing (TTM) | 1.071M |
Ratings
Profile
Edit
| Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. |
| URL | https://www.passagebio.com |
| Investor Relations URL | https://investors.passagebio.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 05, 2022 (est.) |
| Last Earnings Release | May. 16, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| PASG Tweets |